Shruti Rajesh Patel

Racial disparities in molecular testing among patients with early-onset metastatic pancreatic ductal adenocarcinoma.

Nadia Kirmani, Rania Abdusumad, Adhvaith Balakrishnan, Quang Trinh et autres

e13752 Background: Germline and somatic genetic testing are considered standard of care for patients with pancreatic ductal adenocarcinoma (PDAC) per NCCN guidelines. Early-onset PDAC in particular has a higher likelihood of an underlying hereditary predisposition, warranting genetic evaluation as part of the …

us (code pays fourni par la source)

Sex-based differences in metastasis among patients with early-onset pancreatic ductal adenocarcinoma.

Nadia Kirmani, Rania Abdusumad, Adhvaith Balakrishnan, Quang Trinh et autres

e16423 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by early systemic dissemination and a strong predilection for liver metastasis. The incidence of early-onset PDAC is rising, yet sex-specific patterns of metastasis remain poorly characterized. Preclinical evidence demonstrates that sex hormones, immune composition, …

us (code pays fourni par la source)

Exploiting arginine auxotrophy in Philadelphia-chromosome positive acute lymphoblastic leukemia to deliver personalised metabolomic treatment

Michael J. Austin, Shruti Rajesh Patel, Ronas Taner Kesmez, Foteini Kalampalika et autres

Abstract Background Asparagine depletion with asparaginase exemplifies the successful therapeutic exploitation of metabolic dependencies in acute lymphoblastic leukaemia (ALL). However, its clinical utility is frequently constrained by toxicity, resistance mechanisms, and heterogeneous responses; underscoring a need for more precise, stratified approaches to …

Retrospective study comparing predicted and measured resting energy expenditure in burn patients with obesity

Genesy Aickareth, Suyash Jain, Shruti Rajesh Patel, Jad F. Zeitouni et autres

us (code pays fourni par la source)

The impact of a VA teleoncology program on travel burden and costs for veterans with genitourinary cancers.

Karthik Rayapureddi, Shruti Rajesh Patel, Jenni Chang, Lakedia Charman Banks et autres

567 Background: Veterans with genitourinary (GU) cancers often face geographic barriers to subspecialty care, leading to significant travel-related time and cost burdens. To address this, the Veterans Health Administration (VHA) launched regional teleoncology programs, including the VISN 21 Clinical Resource Hub (CRH). …

in, us (code pays fourni par la source)

Assessing the financial implications of translating oncology clinical trial informed consent forms in the U.S.

Shruti Rajesh Patel, Katarina Wang, Ana I. Velazquez Mañana, Narjust Florez et autres

53 Background: Language barriers affect millions in the US, where nearly 8% of individuals (~ 26 million) have limited English proficiency, making it harder to access, understand, and engage with healthcare services. As clinical trials enroll increasingly diverse participants, ensuring the accessibility …

us (code pays fourni par la source)

Immunotherapy Efficacy in Mismatch Repair–Proficient Colorectal Cancer Patients With and Without Liver Metastases

Evan R. Beiter, Shruti Rajesh Patel, Christopher T. Chen

us (code pays fourni par la source)

Invisible in the Metrics of Academic Oncology

Shruti Rajesh Patel, Stephanie L. Graff

us (code pays fourni par la source)

Exploring targets in oropharyngeal cancer – association with immune markers and AI‐scoring of B7‐H3 expression

Jacklyn Liu, Helen Bewicke‐Copley, Shruti Rajesh Patel, Oscar Emanuel et autres

Publication status: Published

gb, de, at, es (code pays fourni par la source)

Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants—a randomized, open-label, three-period, crossover study

Yoon Jin Cha, Tycho Heimbach, Shruti Rajesh Patel, Tian Zhao et autres

ABSTRACT Molnupiravir, a prodrug of β-D-N 4 -hydroxycytidine (NHC), is administered orally as four 200 mg capsules twice daily for 5 days to treat COVID-19. This randomized, open-label, four-treatment sequence, three-period crossover study (NCT06615869) evaluated the bioequivalence of a new single 400 …

us (code pays fourni par la source)

Biodegradable temporizing matrix utilization on a pediatric burn following an exploratory laparotomy

Namratha Mohan, Shruti Rajesh Patel, Genesy Aickareth, John Griswold et autres

Biodegradable temporizing matrix (BTM) is a synthetic polymer used to promote new tissue growth in full-thickness wounds by providing a framework for additional tissue coverage of a new fascial closure, demonstrating its potential for use in recent incision closure and wound healing. …

us (code pays fourni par la source)

Redefining Available Therapy in Oncology Accelerated Approval Decisions

Shruti Rajesh Patel, Maya Kavita Ramachandran, Angela Ai, Christopher T. Chen

When weighing rapid approval for follow-on drugs, should @FDAOncology recognize the drugs that came before?

us (code pays fourni par la source)